Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

Cancer Research
Darren W DavisDavid J McConkey

Abstract

Vascular endothelial growth factor (VEGF) is a key angiogenic factor in a variety of solid tumors, making it one of the most attractive therapeutic targets. VEGF promotes the proliferation, survival, and differentiation of vascular endothelial cells by stimulating autophosphorylation and activation of VEGF receptor-2 (VEGFR-2, fetal liver kinase-1, and kinase insert domain-containing receptor). We developed fluorescence-based, quantitative methods to measure total VEGFR-2, VEGFR-2 phosphorylation, apoptosis, and microvessel density and size within whole tumor cross-sections using a laser scanning cytometer. Using these methods, we characterized the effects of DC101, a blocking antibody specific for murine VEGFR-2, on orthotopic human 253J-BV bladder tumors growing in nude mice. Basal levels of receptor phosphorylation were heterogeneous, with approximately 50% of endothelial cells positive for phosphorylated VEGFR-2 at baseline. DC101 therapy resulted in a 50% decrease in overall VEGFR-2 phosphorylation and a 15-fold and 8-fold increase in endothelial cell (CD31-positive) and tumor cell apoptosis, respectively. DC101 also decreased overall tumor microvessel density, but it mostly affected smaller CD105-negative microvessels loc...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Apr 1, 1996·The Journal of Pathology·P KumarC Bernabeu
Jun 1, 1997·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·K Norrby
Apr 1, 1998·Journal of the National Cancer Institute·J YonedaI J Fidler
May 29, 1999·Science·D Y LiD P Wendel
Sep 20, 2000·The Journal of Experimental Medicine·D W DavisD J McConkey
Feb 24, 2001·Cancer Metastasis Reviews·D M McDonald, A J Foss
Feb 24, 2001·Cancer Metastasis Reviews·G L Semenza
Jun 23, 2001·Neoplasia : an International Journal for Oncology Research·S OzawaI J Fidler
May 23, 2002·Current Opinion in Chemical Biology·Martin TrepelRenata Pasqualini
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstJames L Abbruzzese
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold F Dvorak
Nov 30, 2002·Expert Opinion on Investigational Drugs·Paul W ManleyJeanette M Wood
Jan 18, 2003·International Journal of Cancer. Journal International Du Cancer·Fabian KiesslingStefan Delorme
Mar 12, 2003·The Journal of Urology·Markus HeuserBernhard Hemmerlein
May 30, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sarah E DuffShant Kumar
Jun 13, 2003·Seminars in Oncology·Nishan H Fernando, Herbert I Hurwitz
Jun 24, 2003·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Reda S SaadJan F Silverman
Jul 3, 2003·British Journal of Cancer·D W DavisR S Herbst
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Darren W DavisDavid J McConkey

❮ Previous
Next ❯

Citations

Aug 30, 2007·Cancer Metastasis Reviews·Peter C Black, Colin P N Dinney
Dec 10, 2009·Cancer Metastasis Reviews·Simon J Dovedi, Barry R Davies
Apr 2, 2009·Current Oncology Reports·Aymen A Elfiky, Jonathan E Rosenberg
Jul 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lee S RosenMichael S Gordon
Jan 9, 2010·American Journal of Respiratory and Critical Care Medicine·Ingrid HennekeClemens Ruppert
Dec 3, 2008·Disease Models & Mechanisms·Ann Richmond, Yingjun Su
Jan 22, 2014·Current Oncology Reports·Lee S RosenDaniela E Matei
Jun 25, 2014·Nature Reviews. Urology·Woonyoung ChoiDavid J McConkey
Jun 14, 2005·Expert Opinion on Therapeutic Targets·Nicholas W ChoongRavi Salgia
Jun 23, 2009·Expert Opinion on Drug Delivery·M WirthF Gabor
Sep 19, 2007·Expert Opinion on Emerging Drugs·Piyush K AgarwalColin P N Dinney
Jan 10, 2013·PloS One·Diana MarkleinHeidi Hahn
Jun 12, 2016·Pharmacology & Therapeutics·Beverly L FalconBronislaw Pytowski
Nov 3, 2010·Critical Reviews in Oncology/hematology·Antonio Rodriguez-ArizaNuria Barbarroja
Oct 3, 2008·Gynecologic Oncology·Debra L RichardsonLarry J Copeland
Jan 7, 2011·Clinical Genitourinary Cancer·Emmanuel S Antonarakis, Michael A Carducci
May 3, 2005·The Urologic Clinics of North America·Liana AdamColin P N Dinney
Apr 17, 2012·Gynecologic Oncology·Flora ZagouriRupert Bartsch
Jul 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Jing LiPaul M Harari
May 13, 2008·Cancer Treatment Reviews·Xuenong ZouCody Bünger
Apr 20, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hannes SteinerZ Culig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2022 Meta ULC. All rights reserved